貧血是慢性腎病的重要并發(fā)癥之一。隨著慢性腎病的發(fā)展,貧血的發(fā)病率也隨之不斷升高。roxadustat是一種新型的口服低氧誘導(dǎo)因子脯氨酰羥化酶抑制劑,可誘導(dǎo)內(nèi)源性紅細(xì)胞生成素升高,無論是尚未接受透析的慢性腎病患者,還是需要透析治療的末期腎病患者,roxadustat都能治療貧血并保持一定的血紅蛋白水平,且耐受良好,能夠?yàn)槟I性貧血患者提供更加安全便利的治療。

Anemia is one of the most important complications of chronic kidney disease (CKD). The prevalence of anemia also increases with the progression of CKD. Roxadustat is a novel oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), which can induce the increase of erythropoietin. It can cure anemia and maintain the level of hemoglobin in CKD patients not yet receiving dialysis but also patients in end-stage renal disease receiving dialysis. Roxadustat is well tolerated, and may provide a safer and more convenient treatment for patients with CKD anemia.